# REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

> **NCT07476339** · PHASE4 · NOT_YET_RECRUITING · sponsor: **CAN Community Health** · enrollment: 200 (estimated)

## Conditions studied

- HIV -1 Infection
- HIV (Human Immunodeficiency Virus)
- HIV
- HIV 1 Infection

## Interventions

- **DRUG:** Bictegravir, emtricitabine, and tenofovir alafenamide

## Key facts

- **NCT ID:** NCT07476339
- **Lead sponsor:** CAN Community Health
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-23
- **Primary completion:** 2026-10-23
- **Final completion:** 2026-10-23
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07476339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07476339, "REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07476339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*